Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G Edesa Biotech, Inc. Filed by: Stonepine Capital Management, LLC

August 26, 2026 4:41 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 703,739 shares of Common Shares and (2) warrants to acquire 250,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 13,503,723 shares of Common Shares outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on August 20, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 703,739 shares of Common Shares and (2) warrants to acquire 250,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 13,503,723 shares of Common Shares outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on August 20, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 703,739 shares of Common Shares and (2) warrants to acquire 250,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 13,503,723 shares of Common Shares outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on August 20, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 703,739 shares of Common Shares and (2) warrants to acquire 250,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 13,503,723 shares of Common Shares outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on August 20, 2026.


SCHEDULE 13G



Stonepine Capital Management, LLC
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member
Date:08/26/2026
Stonepine Capital, L.P.
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member of the General Partner, Stonepine GP, LLC
Date:08/26/2026
Stonepine GP, LLC
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member
Date:08/26/2026
Jon M. Plexico
Signature:/s/ Jon M. Plexico
Name/Title:Reporting Person
Date:08/26/2026
Exhibit Information

EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G.

ATTACHMENTS / EXHIBITS

spex99.htm

Categories

SEC Filings